- Is the 2nd Generation Tyrosine Kinase-Inhibitor a Better Initial Therapy Than Imatinib in Persons with Chronic Myeloid Leukemia Presenting in Accelerated Phase: A Multicenter Retrospective StudyYang, Sen; Zhang, Xiaoshuai; Zhang, Yanli; Du, Xin; Weng, Jianyu; Zhu, Huanling; Pan, Ling; Yang, Yun-fan; Meng, Li; Liu, Zhenfang; Liu, Xiaoli; Xu, Na; Chen, Chunyan; Wang, Xiaodong; Liang, Rong; Huang, Jian; Li, Guohui; Liu, Chunshui; Lin, Hai; Hu, Jianda; Fei, Li; Liu, Bingcheng; Li, Weiming; Liu, Zhuogang; Yang, Wei; Huang, Xiao Jun; Jiang, Qian64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), New Orleans, LA, 2022-12-10 To 2022-12-13.
- Imatinib compared with second-generation tyrosine kinase-inhibitors in persons with chronic myeloid leukemia presenting in accelerated phaseYang, Sen; Zhang, Xiaoshuai; Gale, Robert Peter; Du, Xin; Chen, Chun-yan; Weng, Jian-yu; Huang, Jian; Li, Fei; Zeng, Yun; Xiao, Zhen; Hu, Jian-da; Yang, Li-jie; Liu, Zhuo-gang; Li, Guo-hui; Sun, Xiu-li; Yang, Wei; Feng, Ru; Han, Yan-qiu; Jing, Yu; Xu, Na; Liu, Xiao-li; Liu, Zhen-fang; Wang, Xiao-dong; Wu, Shi-xin; Liang, Rong; Zhang, Yan-li; Yang, Yun-fan; Zhu, Huan-ling; Pan, Ling; Meng, Li; Zhao, Yan-hong; Yi, Hai; Liu, Yi-lan; Zhang, Wei-hua; Zheng, Yuan-jun; Zhou, Ze-ping; Chen, Su-ningAmerican Journal of Hematology, 2023, 98(7): E183-E186.
- A Predictive Scoring System for Therapy Failure in Persons with Chronic Myeloid Leukemia Receiving Initial a Second-Generation Tyrosine Kinase Inhibitor TherapyZhang, Xiaoshuai; Liu, Bingcheng; Huang, Jian; Zhang, Gongli; Liu, Xiaoli; Xu, Na; Li, Weiming; Du, Xin; Weng, Jianyu; Lin, Hai; Liang, Rong; Chen, Chunyan; Zhu, Huanling; Pan, Ling; Yang, Yun-fan; Wang, Xiaodong; Li, Guohui; Liu, Zhuogang; Liu, Zhenfang; Hu, Jianda; Liu, Chunshui; Fei, Li; Yang, Wei; Meng, Li; Gale, Robert Peter; Huang, Xiao Jun; Jiang, Qian64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), New Orleans, LA, 2022-12-10 To 2022-12-13.
会议论文
Subjects with Chronic Myeloid Leukemia Identified As Intermediate- or High-Risk Subjects Using the Imatinib Therapy Failure (IMTF) Model Benefit from Initial Therapy with a Second-Generation Tyrosine Kinase Inhibitor
7阅读
